An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 23648912.
- Also identified by DOI 10.1378/chest.12-1604 and PMC identifier 5991580.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.
Medical subject headings
- Cryptococcosis
- Cryptococcus neoformans
- Janus Kinase 1
- Janus Kinase 2
- Opportunistic Infections
- Pneumonia, Bacterial
- Pyrazoles